SCHEMBL5162461

SCHEMBL5162461

CCCCC(I)COC=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CTSK P43235 5/20 0.34
CYP3A4 P08684 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ADH1B P00325 3/20 0.32
ADH1C P00326 3/20 0.32
ADH1A P07327 3/20 0.32
ADH7 P40394 3/20 0.32
ADH4 P08319 2/20 0.31
EPHX1 P07099 1/20 0.31
ATM Q13315 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
TRPV1 Q8NER1 1/20 0.30
ALDH1A1 P00352 1/20 0.30
FAAH O00519 1/20 0.30
FDPS P14324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385559 0.77 TSHR (0.40) TSHRSMN1; SMN2CTSKCYP3A4L3MBTL1
SCHEMBL9346378 0.75 TSHR (0.39) TSHRSMN1; SMN2CTSKCYP3A4L3MBTL1
SCHEMBL96308 0.75 CYP3A4 (0.55) TSHRSMN1; SMN2CYP3A4L3MBTL1ATM
Hydrochloric Acid SCHEMBL29133121 0.75 TSHR (0.39) TSHRSMN1; SMN2CTSKCYP3A4L3MBTL1
SCHEMBL3030523 0.75 TSHR (0.39) TSHRSMN1; SMN2CTSKCYP3A4L3MBTL1
SCHEMBL20723704 0.75 TSHR (0.39) TSHRSMN1; SMN2CTSKCYP3A4ATM
SCHEMBL3040110 0.75 CYP3A4 (0.41) TSHRSMN1; SMN2CTSKCYP3A4L3MBTL1
SCHEMBL9120387 0.75 TSHR (0.39) TSHRSMN1; SMN2CTSKCYP3A4L3MBTL1
SCHEMBL11067291 0.73 CYP3A4 (0.53) TSHRSMN1; SMN2CYP3A4L3MBTL1ATM
SCHEMBL3037098 0.73 TSHR (0.38) TSHRSMN1; SMN2CTSKCYP3A4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0362634-A2 Basic dihydropyridines, process for their preparation and their use as intermediates BAYER AG (DE) 1990-04-11 EP claimed
US-20070129288-A1 Antibacterial amide macrocycles BAYER HEALTHCARE AG (DE) 2007-06-07 US disclosed
EP-1515983-B1 ANTIBACTERIAL AMIDE MACROCYCLES AICURIS GMBH & CO KG (DE) 2007-02-21 EP disclosed
US-20060258571-A1 Antibacterial ester macrocycles AICURIS GMBH & CO. KG (DE) 2006-11-16 US disclosed
EP-1526896-A1 ANTIBACTERIAL ESTER MACROCYCLES Bayer HealthCare AG (DE) 2005-05-04 EP disclosed
EP-1515983-A1 ANTIBACTERIAL AMIDE MACROCYCLES Bayer HealthCare AG (DE) 2005-03-23 EP disclosed
WO-2004012816-A1 ANTIBACTERIAL ESTER MACROCYCLES BAYER HEALTHCARE AG (DE) 2004-02-12 WO disclosed
WO-2003106480-A1 ANTIBACTERIAL AMIDE MACROCYCLES BAYER HEALTHCARE AG (DE) 2003-12-24 WO disclosed
US-5242903-A Enzyme inhibitors BAYER AKTIENGESELLSCHAFT (DE) 1993-09-07 US disclosed
WO-1992010510-A1 DITHIOLANO- AND DITHIANOGLYCIN-CONTAINING RENIN-INHIBITING PEPTIDES, PROCESS FOR PRODUCING THE SAME AND THEIR USE IN MEDICAMENTS BAYER AKTIENGESELLSCHAFT (DE) 1992-06-25 WO disclosed
WO-1992010509-A1 RENIN-INHIBITING PEPTIDES OF THE CYCLOHEXYLSTATIN TYPE, PROCESS FOR PRODUCING THE SAME AND THEIR USE IN MEDICAMENTS BAYER AKTIENGESELLSCHAFT (DE) 1992-06-25 WO disclosed
US-5122610-A Renin inhibitor intermediates BAYER AKTIENGESELLSCHAFT (DE) 1992-06-16 US disclosed
US-5095006-A Enzyme inhibitors BAYER AKTIENGESELLSCHAFT (DE) 1992-03-10 US disclosed
US-5010057-A Treatment of high blood pressure and cardiac insufficiency BAYER AKTIENGESELLSCHAFT (DE) 1991-04-23 US disclosed
EP-0393445-A2 Use of peptide renin inhibitors as an agent against retrovirus BAYER AG (DE) 1990-10-24 EP disclosed
EP-0362634-A2 Basic dihydropyridines, process for their preparation and their use as intermediates BAYER AG (DE) 1990-04-11 EP disclosed
EP-0356796-A2 Aminomethyl peptides, production process and their use as medicaments BAYER AG (DE) 1990-03-07 EP disclosed
US-4818748-A HYPOTENSIVE AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1989-04-04 US disclosed
EP-0236874-A2 Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes BAYER AG (DE) 1987-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129288-A1 Antibacterial amide macrocycles AADAC, AAAS, MRPL21 TSHR 1248/4885SMN1; SMN2 2957/4885CTSK 300/4885
US-20060258571-A1 Antibacterial ester macrocycles TECR, MRPL21, CYP51A1 TSHR 2720/4885SMN1; SMN2 3122/4885CTSK 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.